Candid Health Raises $120M Series D for Revenue Cycle Automation

Candid Health, a frontrunner in autonomous revenue cycle management (RCM) solutions for healthcare providers, has successfully closed a $120 million Series D funding round. This significant capital infusion was spearheaded by Sixth Street Growth, the investment arm focused on scaling companies within the broader Sixth Street platform. The investment underscores the accelerating demand for sophisticated RCM technology capable of streamlining complex financial operations within the healthcare sector.

The funding round saw robust participation from existing backers, including Oak HC/FT, 8VC, and the influential accelerator Y Combinator. This continued support from its investor base highlights strong confidence in Candid Health's strategic direction and its proven ability to deliver substantial value. Notably, this latest financing represents a threefold increase in the company's valuation compared to its Series C round in February 2025, a testament to its rapid growth and market traction.

The healthcare RCM market is a critical, yet often inefficient, segment of the industry, with providers grappling with administrative burdens, claim denials, and payment delays. Industry estimates suggest that inefficient RCM processes can cost U.S. hospitals billions annually. Candid Health's platform addresses these pain points directly by leveraging automation to optimize billing, coding, and collections, thereby improving cash flow and reducing operational overhead for its clients.

Sixth Street Growth's involvement signals a strategic partnership aimed at accelerating Candid Health's expansion and product development. The firm is known for backing high-growth technology companies, and its investment in Candid Health suggests a belief in the company's potential to capture a larger share of the RCM market. This capital will likely fuel further innovation in AI-driven RCM, expand the company's sales and marketing efforts, and potentially support strategic acquisitions.

The healthcare technology sector, particularly areas focused on operational efficiency and financial optimization, has seen sustained investor interest. Companies that can demonstrably reduce costs and improve revenue capture for providers are highly attractive. Candid Health's success in securing this substantial Series D round positions it as a key player in this dynamic market, poised to further solidify its leadership in autonomous RCM solutions.

With this new capital, Candid Health is expected to enhance its platform's capabilities, offering even more advanced automation and analytics to healthcare organizations. The company's focus on an autonomous approach aims to minimize manual intervention, a significant bottleneck in traditional RCM. This strategic advantage is crucial as healthcare systems face increasing pressure to operate more efficiently while navigating evolving reimbursement models and regulatory requirements.